COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • March 22nd, 2017 • TESARO, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 28, 2016 (the “Effective Date”), by and between TESARO, Inc., a Delaware corporation with a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts, United States of America, 02451 (“TESARO Inc.”), TESARO Development Ltd., a Bermuda corporation with a place of business at Clarendon House, 2 Church Street, Hamilton HM 11 Bermuda (“TSRO Ltd.”, and together with “TESARO Inc.”, “TESARO”) and Zai Lab (Shanghai) Co., Ltd. having its principal office at 1043 Halei Road, Building 8, Suite 502, Pudong, Shanghai, P.R. China, 201203 (“ZAI”). TESARO and ZAI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ARTICLE 1 DEFINITIONSCollaboration, Development and License Agreement • January 20th, 2005 • Algorx Pharmaceuticals Inc • Pharmaceutical preparations • New York
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • March 16th, 2007 • Trimeris Inc • Biological products, (no disgnostic substances) • Delaware
This COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), effective as of this 8th day of June, 2005 (the “Effective Date”), is made by and between Trimeris, Inc., having a principal place of business at 3500 Paramount Parkway, Morrisville, North Carolina 27560, U.S.A. (“Trimeris”), and ChemBridge Research Laboratories, Inc. (together with its Affiliates, “CRL”), having a principal place of business at 16981 Via Tazon, Suite K, San Diego, California 92127, U.S.A.
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • January 20th, 2015 • Zosano Pharma Corp • Pharmaceutical preparations • New York
THIS COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 21, 2014 (the “Effective Date”) by and between ZP OPCO, INC. (formerly Zosano Pharma, Inc.), a Delaware corporation and wholly owned subsidiary of Zosano Pharma Corporation, having a place of business at 34790 Ardentech Court, Fremont, California 94555, USA (“Zosano”), and ELI LILLY AND COMPANY, an Indiana corporation, with its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”).
Amendment to Collaboration, Development and License AgreementCollaboration, Development and License Agreement • April 30th, 2018 • Zai Lab LTD • Pharmaceutical preparations • New York
THIS AMENDMENT TO COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of February 26, 2018 by and among Tesaro, Inc., a Delaware corporation (“Tesaro Inc.”), Tesaro Development Ltd., a Bermuda corporation (“TSRO Ltd.” and together with Tesaro Inc., “Tesaro”), and Zai Lab (Shanghai) Co., Ltd., a limited liability company organized under the laws of the People’s Republic of China (“Zai” and together with Tesaro, the “Parties”).
AMENDMENT NO. 1 TO COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • August 17th, 2015 • Zosano Pharma Corp • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is made and entered into as of August 11, 2015, by and between ZP Opco, Inc., a Delaware corporation (“Zosano”), and Eli Lilly and Company (“Lilly”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Collaboration Agreement (as defined below).
Collaboration, Development and License AgreementCollaboration, Development and License Agreement • February 28th, 2018 • TESARO, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT TO COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of February 26, 2018 by and among TESARO, Inc., a Delaware corporation (“TESARO Inc.”), TESARO Development Ltd., a Bermuda corporation (“TSRO Ltd.” and together with TESARO Inc., “TESARO”), and Zai Lab (Shanghai) Co., Ltd., a limited liability company organized under the laws of the People’s Republic of China (“Zai” and together with TESARO, the “Parties”).
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • February 28th, 2017
THIS COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “ Agreement ”) is made and entered into as of September 28, 2016 (the “ Effective Date ”), by and between TESARO, Inc. , a Delaware corporation with a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts, United States of America, 02451 (“ TESARO Inc. ”), TESARO Development Ltd., a Bermuda corporation with a place of business at Clarendon House, 2 Church Street, Hamilton HM 11 Bermuda (“ TSRO Ltd. ”, and together with “ TESARO Inc. ”, “ TESARO ”) and Zai Lab (Shanghai) Co., Ltd. having its principal office at 1043 Halei Road, Building 8, Suite 502, Pudong, Shanghai, P.R. China, 201203 (“ ZAI ”). TESARO and ZAI are sometimes referred to herein individually as a “ Party ” and collectively as the “ Parties .”
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • August 15th, 2017 • Zai Lab LTD • Pharmaceutical preparations • New York
THIS COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 28, 2016 (the “Effective Date”), by and between TESARO, Inc., a Delaware corporation with a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts, United States of America, 02451 (“TESARO Inc.”), TESARO Development Ltd., a Bermuda corporation with a place of business at Clarendon House, 2 Church Street, Hamilton HM 11 Bermuda (“TSRO Ltd.”, and together with “TESARO Inc.”, “TESARO”) and Zai Lab (Shanghai) Co., Ltd. having its principal office at 1043 Halei Road, Building 8, Suite 502, Pudong, Shanghai, P.R. China, 201203 (“ZAI”). TESARO and ZAI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION, DEVELOPMENT AND LICENSE AGREEMENTCollaboration, Development and License Agreement • June 24th, 2014 • Zosano Pharma Corp • Pharmaceutical preparations • New York
In order to ensure timely settlement of invoices, you are kindly requested to observe the below guidelines when sending invoices or credit notes to Novo Nordisk.
